RedHill Biopharma Ltd (RDHL): RedHill to get US patent linked to bacte...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	144
Posts	27610
Boards Moderated	3
Alias Born	02/07/2004

midastouch017

Re: None

Thursday, 01/26/2023 8:41:10 AM

Thursday, January 26, 2023 8:41:10 AM

RedHill to get US patent linked to bacterial infection drug

Jan. 26, 2023 8:35 AM ETRedHill Biopharma Ltd. (RDHL)

By: Ravikash, SA News Editor

RedHill Biopharma (NASDAQ:RDHL) said that the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for a patent covering RHB-204's oral fixed-dose combination, methods treating pulmonary Mycobacterium avium Complex (MAC) disease.

The patent will also cover kits comprising a supply of fixed-dose combination products for treating pulmonary MAC disease.

The company added that RHB-204 is currently undergoing a phase 3 trial in the U.S. as the first stand-alone standard of care first-line therapy for Non-tuberculosis Mycobacteria (NTM) disease caused by MAC infection.

MAC is a group of bacteria causing lung diseases.

The patent is expected to protect RHB-204 through 2041.

RedHill noted that it is advancing discussions with several prospective partners for RHB-204 in multiple territories.